Results 101 to 110 of about 19,649 (222)

Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib

Biologics: Targets & Therapy, 2016
Josephine Emole,1 Taiwo Talabi,2 Javier Pinilla-Ibarz1 1Department of Malignant Hematology, 2Moffitt Program for Outreach Wellness Education and Resources, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA Abstract: Chronic myelogenous ...
Emole J, Talabi T, Pinilla-Ibarz J
doaj  

Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. [PDF]

, 2013
PurposeDasatinib is a prototypic short half-life BCR-ABL1 tyrosine kinase inhibitor. The recommended dose of dasatinib for chronic myeloid leukemia in chronic phase was changed from 70 mg twice daily to 100 mg once daily following a Phase III dose ...
Chen, Tai-Tsang, Hochhaus, Andreas, Kantarjian, Hagop M, Roy, Amit, Shah, Neil P, Wang, Xiaoning   +5 more
core   +2 more sources

A Case of Hepatocellular Carcinoma after Treatment for Chronic Myeloid Leukemia in a Patient without Liver Disease

Case Reports in Oncology
Introduction: Chronic myeloid leukemia (CML) is a myeloproliferative disease caused by the reciprocal translocation of chromosomes 9 and 22, which leads to a chimeric gene product known as BCR-ABL.
Darshankumar M. Raval, Ricardo J. Pagán, Shayan Butt, Libardo Rueda Prada   +3 more
doaj   +1 more source

Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

Revista Brasileira de Hematologia e Hemoterapia, 2012
BACKGROUND: Chronic myeloid leukemia is a neoplasm characterized by clonal expansion of hematopoietic progenitor cells resulting from the (9:22)(q34,11) translocation.
Maria Juracy Petrola, Alana Joselina Montenegro de Castro, Maria Helena da Silva Pitombeira, Maritza Cavalcante Barbosa, Acy Telles de Souza Quixadá, Fernando Barroso Duarte, Romelia Pinheiro Gonçalves   +6 more
doaj   +1 more source

CDK8/19 inhibition attenuates G1 arrest induced by BCR-ABL antagonists and accelerates death of chronic myelogenous leukemia cells

Cell Death Discovery
Imatinib mesylate (IM) and other BCR-ABL tyrosine kinase inhibitors (BCR-ABLi) are the mainstay of chronic myelogenous leukemia (CML) treatment. However, activation of circumventing signaling pathways and quiescence may limit BCR-ABLi efficacy.
Alvina I. Khamidullina, Margarita A. Yastrebova, Alexandra V. Bruter, Julia V. Nuzhina, Nadezhda E. Vorobyeva, Anastasia M. Khrustaleva, Ekaterina A. Varlamova, Alexander V. Tyakht, Iaroslav E. Abramenko, Ekaterina S. Ivanova, Maria A. Zamkova, Jing Li, Chang-Uk Lim, Mengqian Chen, Eugenia V. Broude, Igor B. Roninson, Alexander A. Shtil, Victor V. Tatarskiy   +17 more
doaj   +1 more source

Diversity of breakpoints of variant Philadelphia chromosomes in chronic myeloid leukemia in Brazilian patients

Revista Brasileira de Hematologia e Hemoterapia, 2015
Background: Chronic myeloid leukemia is a myeloproliferative disorder characterized by the Philadelphia chromosome or t(9;22)(q34.1;q11.2), resulting in the break-point cluster regionAbelson tyrosine kinase fusion gene, which encodes a constitutively ...
Maria de Lourdes Lopes Ferrari Chauffaille, Ana Carolina de Almeida Bandeira, Aline Schiavoni Guarnieri da Silva   +2 more
doaj   +1 more source

The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era

Revista Brasileira de Hematologia e Hemoterapia, 2011
Tyrosine kinase inhibitors have changed the management and outcomes of chronic myeloid leukemia patients. Quantitative polymerase chain reaction is used to monitor molecular responses to tyrosine kinase inhibitors.
Ilana Zalcberg Renault, Vanesa Scholl, Rocio Hassan, Paola Capelleti, Marcos de Lima, Jorge Cortes   +5 more
doaj   +1 more source

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival [PDF]

, 2012
Recent evidence suggests CML stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated patients. We investigated whether CML stem cells, in a transgenic mouse model of CML-like disease or derived from ...
Anderson, Ashley Hamilton, Bhatia, Bin Zhang, Branford, Carsten Müller-Tidow, Chen, Chomel, Chu, Copland, Corbin, Daley, Druker, Druker, Druker, Elaine K. Allan, Felsher, Franck E. Nicolini, G. Vignir Helgason, Gabert, Gorre, Gothert, Graham, Hamilton, Hayette, Holyoake, Hughes, Hurtz, Jiang, Jordan, Jordanides, Jorgensen, Konig, Konig, Konig, Koschmieder, Li, Lombardo, Lugo, Mirle Schemionek, Myssina, Notta, Pellicano, Ravi Bhatia, Samanta, Samanta, Schemionek, Scott, Shachaf, Shah, Sharma, Sharma, Sobrinho-Simoes, Steffen Koschmieder, Svetlana Myssina, Talpaz, Tessa L. Holyoake, Valerie G. Brunton, Wang, Weinstein, Weisberg, White   +61 more
core   +2 more sources

Pediatric chronic myeloid leukemia in myeloid blast crisis

Autopsy and Case Reports, 2023
Chronic myeloid leukemia (CML) accounts for 2-3% of childhood leukemias. About 5% of cases present in a blastic phase of CML which clinically and morphologically mimics more common acute leukemias of childhood.
Biswajit Dey, Anirban Dutta
doaj  

Novel prognostic factors in chronic myeloid leukemia [PDF]

, 2008
Chronic myeloid leukemia (CML) is a malignant clonal blood disease that originates from a pluripotent hematopoietic stem cell. The cytogenetic hallmark of CML, the Philadelphia chromosome (Ph), is formed as a result of reciprocal translocation between ...
Lundán, Tuija
core